Table 4.
Multivariate analysis of OS and DFS in 260 acute myeloid leukemia patients examined for treatment outcomes
| OS | DFS | |||
|---|---|---|---|---|
| P‐value | HR (95% CI) | P‐value | HR (95% CI) | |
| GS vs non‐GS | 0.651 | 1.11 (0.70–1.76) | 0.008 | 1.72 (1.16–2.57) |
| Age (≤50 vs > 50) (years) | 0.007 | 1.60 (1.13–2.25) | 0.433 | 1.14 (0.83–1.56) |
| Sex | 0.229 | 1.23 (0.88–1.71) | 0.363 | 1.16 (0.84–1.59) |
| WBC (≤20 000 vs > 20 000) | 0.079 | 0.74 (0.53–1.04) | 0.683 | 0.94 (0.68–1.29) |
| Cytogenetic subgroups | <0.001 | 2.19 (1.58–3.02) | <0.001 | 2.00 (1.46–2.73) |
| FAB (M4, or M5 vs others) | 0.877 | 0.97 (0.66–1.43) | 0.900 | 1.02 (0.72–1.45) |
CI, confidence interval; DFS, disease‐free survival; FAB, French–American–British; GS, granulocytic sarcoma; HR, hazard ratio; OS, overall survival; WBC, white blood cells.